Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
1 hedge funds and large institutions have $9 invested in Sage Therapeutics in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
0.05% less ownership
Funds ownership: 0.05% → 0% (-0.05%)
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $39K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$35.1K |
| 2 |
IFP Advisors
Tampa,
Florida
|
-$3.86K |
SAGE Hedge Fund Activity: Q4 2025 in Review
1 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2025, worth a combined $9 — down 100% from $39K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SAGE and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Osaic Holdings, exiting entirely with an estimated $35.1K sold.
- 1 institutional investor held Sage Therapeutics (SAGE) as of Q4 2025, down from 4 in Q3 2025.
- Funds reported $9 of Sage Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Sage Therapeutics positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Sage Therapeutics seller in Q4 2025 was Osaic Holdings, an estimated $35.1K sold.
Based on aggregated 13F filings for Q4 2025.